Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19
- PMID: 38302942
- PMCID: PMC10835856
- DOI: 10.1186/s12916-023-03235-5
Substantial health and economic burden of COVID-19 during the year after acute illness among US adults not at high risk of severe COVID-19
Abstract
Background: Patients recovering from SARS-CoV-2 infection and acute COVID-19 illness can experience a range of long-term post-acute effects. The potential clinical and economic burden of these outcomes in the USA is unclear. We evaluated diagnoses, medications, healthcare utilization, and medical costs before and after acute COVID-19 illness in US patients who were not at high risk of severe COVID-19.
Methods: This study included eligible adults who were diagnosed with COVID-19 from April 1 to May 31, 2020, who were 18 - 64 years of age, and enrolled within Optum's de-identified Clinformatics® Data Mart Database for 12 months before and 13 months after COVID-19 diagnosis. Patients with any condition or risk factor placing them at high risk of progression to severe COVID-19 were excluded. Percentages of diagnoses, medications, healthcare utilization, and costs were calculated during baseline (12 months preceding diagnosis) and the post-acute phase (12 months after the 30-day acute phase of COVID-19). Data were stratified into 3 cohorts according to disposition during acute COVID-19 illness (i.e., not hospitalized, hospitalized without intensive care unit [ICU] admission, or admitted to the ICU).
Results: The study included 3792 patients; 56.5% of patients were men, 44% were White, and 94% did not require hospitalization. Compared with baseline, patients during the post-acute phase had percentage increases in the diagnosis of the following disorders: blood (166%), endocrine and metabolic (123%), nervous system (115%), digestive system (76%), and mental and behavioral (75%), along with increases in related prescriptions. Substantial increases in all measures of healthcare utilization were observed among all 3 cohorts. Total medical costs increased by 178% during the post-acute phase. Those who were hospitalized with or without ICU admission during the acute phase had the greatest increases in comorbidities and healthcare resource utilization. However, the burden was apparent across all cohorts.
Conclusions: As evidenced by resource use in the post-acute phase, COVID-19 places a significant long-term clinical and economic burden among US individuals, even among patients whose acute infection did not merit hospitalization.
Keywords: COVID-19; Long COVID; PASC; Post-COVID conditions; SARS-CoV-2.
© 2024. The Author(s).
Conflict of interest statement
AS, WA, RC, MR, MB, FD, and JA are employees of Pfizer Inc and may hold stock or stock options. TM is an employee of Quanticate, which receives consulting fees from Pfizer Inc.
Figures
Similar articles
-
Substantial health and economic burden of COVID-19 during the year after acute illness among US adults at high risk of severe COVID-19.BMC Med. 2024 Feb 1;22(1):46. doi: 10.1186/s12916-023-03234-6. BMC Med. 2024. PMID: 38303065 Free PMC article.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Examining potential Long COVID effects through utilization of healthcare resources: a retrospective, population-based, matched cohort study comparing individuals with and without prior SARS-CoV-2 infection.Eur J Public Health. 2024 Jun 7;34(3):592-599. doi: 10.1093/eurpub/ckae001. Eur J Public Health. 2024. PMID: 38243748 Free PMC article.
-
Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.Lancet Psychiatry. 2022 Oct;9(10):815-827. doi: 10.1016/S2215-0366(22)00260-7. Epub 2022 Aug 17. Lancet Psychiatry. 2022. PMID: 35987197 Free PMC article.
-
A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.BMC Infect Dis. 2021 Jul 13;21(1):677. doi: 10.1186/s12879-021-06359-2. BMC Infect Dis. 2021. PMID: 34256735 Free PMC article.
Cited by
-
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial.Vaccines (Basel). 2024 Jul 2;12(7):734. doi: 10.3390/vaccines12070734. Vaccines (Basel). 2024. PMID: 39066372 Free PMC article.
References
-
- Bull-Otterson L, Baca S, Saydah S, Boehmer TK, Adjei S, Gray S, et al. Post-COVID conditions among adult COVID-19 survivors aged 18–64 and ≥65 years — United States, March 2020–November 2021. MMWR Morb Mortal Wkly Rep. 2022;71(21):713–717. doi: 10.15585/mmwr.mm7121e1. - DOI
-
- Centers for Disease Control and Prevention. Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long COVID". Available at: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm. Accessed 6 Sept 2022.
-
- World Health Organization. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. World Health Organization. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_cond.... Accessed 8 Jun 2022.
-
- Centers for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-c.... Accessed 23 Jun 2022.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous